Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus

Abstract

The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. The combination can be useful during and following radiation exposure to ameliorate the inflammatory response.

1 .- 23 . (canceled) 
     
     
         24 . A method of treating a viral infection in a patient, wherein the viral infection is caused by coronavirus, the method comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast. 
     
     
         25 . The method of  claim 24 , wherein the viral infection is a viral respiratory tract infection. 
     
     
         26 . The method of  claim 24 , wherein the combination is administered at the onset of symptoms. 
     
     
         27 . The method of  claim 24 , wherein the combination is administered in a sequential manner. 
     
     
         28 . The method of  claim 24 , wherein the combination is administered in a substantially simultaneous manner. 
     
     
         29 . The method of  claim 24 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral. 
     
     
         30 . The method of  claim 24 , wherein the levocetirizine and montelukast are administered by the same route. 
     
     
         31 . The method of  claim 24 , wherein the combination further comprising a steroid. 
     
     
         32 . The method of  claim 24 , wherein the combination further comprising a antiviral agent. 
     
     
         33 . A method of treating acute inflammation in a patient in need thereof comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast, wherein the acute inflammation is caused by a viral infection, wherein the viral infection is caused by coronavirus. 
     
     
         34 . The method of  claim 33 , wherein the combination is administered at the onset of symptoms. 
     
     
         35 . The method of  claim 33 , wherein the combination is administered in a sequential manner. 
     
     
         36 . The method of  claim 33 , wherein the combination is administered in a substantially simultaneous manner. 
     
     
         37 . The method of  claim 33 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral. 
     
     
         38 . The method of  claim 33 , wherein the levocetirizine and montelukast are administered by the same route. 
     
     
         39 . The method of  claim 33 , wherein the combination further comprising a steroid. 
     
     
         40 . The method of  claim 33 , wherein the combination further comprising a antiviral agent. 
     
     
         41 . A method of treating acute nasal and sinus inflammation in a patient in need thereof comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast, wherein the acute inflammation is caused by a viral infection, wherein the viral infection is caused by coronavirus.